Dublin, Nov. 13, 2018 (GLOBE NEWSWIRE) -- The "Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global amyloidosis treatment market size is expected to reach USD 6.7 billion by 2025, registering a 7.2% CAGR during the forecast period.

Several factors such as increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are driving the market.

Amyloidosis is a group of rare diseases where misfolded aggregates of proteins (amyloids) buildup in tissues and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority of cases, the disease is diagnosed in people over the age of 60, there are a few cases of people being diagnosed in their late 20s and about two-thirds of the patients are male.

Among treatments, chemotherapy held the largest share in 2017, followed by targeted therapy, and supportive care. However, targeted therapies are expected to dominate the market in 2025, supported by a strong pipeline and potential approval of drugs such as Alnylam's Onpattro, Ionis' Tegsedi, Johnson & Johnson's Darzalex, and Takeda's Ninlaro.

Stem cell transplants and targeted therapies are gaining traction in developed countries. However, amyloidosis cohorts in endemic regions do not have access to sufficient healthcare infrastructure to ensure prompt diagnosis and treatment in underdeveloped countries. Chemotherapy and supportive care are anticipated to lose market share over the forecast period due to adverse side effects and lower efficacy.

Further key findings from the report suggest:

• An estimated 16,000 people in U.S. suffer from amyloidosis, with approximately 3,000 to 4,000 new cases being reported annually
• U.S. dominated the global amyloidosis treatment market, with a share of more than 27.0% in 2017 due to potential launch of pipeline drugs, increased adoption of novel therapeutics, and high cost of treatment in the country
• Chemotherapy dominated the amyloidosis treatment market, with a share of about 35.0% in 2017. Targeted therapies are projected to witness double-digit growth during the forecast period due to multiple product approvals
• Emerging markets for amyloidosis such as China, Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show attractive growth over the forecast period due to improved healthcare infrastructure, favorable government policies, increased investment, and large amyloidosis cohort
• Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda are some of the key players operating in this market
• Currently, 19 products are under evaluation for amyloidosis treatment in various stages of clinical development. Promising pipeline candidates such as Onpattro, Vyndaqel, Tegsedi, Darzalex, and Ninlaro are expected to generate significant revenue upon launch.

Key Topics Covered:

Chapter 1 Report Scope
1.1 Treatment Scope
1.2 Country Scope
1.3 Estimates and Forecast Timeline

Chapter 2 Methodology
2.1 Research Methodology
2.1.1 Information procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 List of Sources
2.5 List of Abbreviations

Chapter 3 Objectives
3.1 Objective - 1: Understanding the market dynamics
3.2 Objective - 2: Understanding the trends & variables in the individual countries
3.3 Objective - 3: Understanding the attributes such as strategy framework
3.4 Objective - 4: Understanding the key service and application scopes

Chapter 4 Executive Summary

Chapter 5 Disease Primer and Epidemiology
5.1 Disease Primer
5.1.1 Types
5.1.1.1 AL Amyloidosis
5.1.1.2 AA Amyloidosis
5.1.1.3 Transthyretin Amyloidosis (ATTR)
5.1.2 Diagnosis
5.2 Epidemiology
5.2.1 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
5.2.2 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
5.2.2.1 U.S.
5.2.2.2 Japan
5.2.2.3 U.K.
5.2.2.4 Germany
5.2.2.5 France
5.2.2.6 Spain
5.2.2.7 Italy

Chapter 6 Global Amyloidosis Market Overview
6.1 Market, by Treatment
6.1.1 Chemotherapy
6.1.2 Supportive Care
6.1.3 Surgery
6.1.4 Stem Cell Transplant (SCT)
6.1.5 Targeted Therapy
6.2 Market, by Country
6.2.1 U.S.
6.2.2 Japan
6.2.3 U.K.
6.2.4 Germany
6.2.5 France
6.2.6 Spain
6.2.7 Italy
6.2.8 RoW
6.3 Market Size & Forecast
6.3.1 Sales Performance
6.3.1.1 Sales Performance, by Treatment (2017 - 2025)
6.3.1.2 Sales Performance, by Country (2017 - 2025)
6.4 Amyloidosis Market: Drivers and Restraints
6.5 M&A, Deal Landscape (2014-2018 YTD)
6.6 SWOT

Chapter 7 Global Amyloidosis Market: Pipeline Intelligence
7.1 Pipeline Landscape
7.1.1 Leading Drugs in Development
7.1.2 Key R&D Trends
7.2 Promising Drug Candidates in Pipeline
7.2.1 Late Stage Pipeline Analysis
7.2.2 Profile of Disruptive Drugs
7.2.2.1 Vyndaqel (tafamidis)
7.2.2.2 Onpattro (patisiran)
7.2.2.3 Tegsedi (inotersen)
7.2.2.4 Darzalex (daratumumab)
7.2.2.6 Ninlaro (ixazomib)
7.2.2.7 GSK2398852 (dezamizumab)
7.2.2.8 Pomalyst (pomalidomide)
7.2.2.9 ALN-TTRsc02
7.2.2.10 CAEL101
7.3 Global Pipeline Forecast

Chapter 8 Company Profiles
8.1 Pfizer
8.2 Ionis Pharmaceuticals
8.3 Alnylam Pharmaceuticals
8.4 Johnson & Johnson
8.5 Takeda

Chapter 9 Market Outlook
9.1 Winners and Losers
9.2 Emerging Companies
9.2.1 Eidos Therapeutics
9.2.2 Corino Therapeutics
9.2.3 GlaxoSmithKline
9.2.4 Prothena
9.2.5 Caelum Biosciences
9.3 What the Future Holds

For more information about this report visit https://www.researchandmarkets.com/research/dxmgsg/global?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs